Scientists at The Institute of Cancer Research, London, are teaming up with small molecule neoantigen immuno-oncology company NeoPhore to develop new potential cancer drugs.

A new, oral ‘first in class’ experimental cancer drug has shown potent activity against cancer cells and caused shrinkage of hard-to-treat human ovarian tumours grown in mice, a new study shows.

Upcoming events will give industry experts the chance to hear from some of our leading researchers about opportunities to work with them.